Currentmedical mutual - ohioPolicy N/A

C1 esterase inhibitor prophylaxis (Cinryze, Haegarda)

Policy governing prior authorization, coverage criteria, dosing, and site-of-care management for Cinryze and Haegarda for long-term prophylaxis of hereditary angioedema (HAE) in eligible members.

Policy Summary

Payermedical mutual - ohio

PolicyC1 esterase inhibitor prophylaxis (Cinryze, Haegarda)

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateN/A

Key ActionPrior authorization is required for Cinryze (J0598) and Haegarda (J0599); ensure documentation meets policy criteria and confirm site-of-care requirements.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

J0598,J0599HCPCS codes requiring prior approval

≥6 yrsMinimum age for coverage

1 yrInitial authorization duration

IV/SubQDosing guidance present

Coverage Criteria

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Initial HAE prophylaxis criteria

A. Diagnosis confirmed: a. Functional C1-INH protein level < 50% of normal (per lab reference) AND b. Serum C4 < 14 mg/dL AND C1-INH level < 19.9 mg/dL
B. Prescriber: Medication is prescribed by or in consultation with an allergist, immunologist, hematologist, or a physician specializing in HAE or related disorders
C. Age: If the requested drug is Cinryze or Haegarda, patient is 6 years of age or older
D. Site of care: Site-of-care medical necessity is met (site-of-care management applies)

Concomitant therapy and acute use exclusions: The requested medication will not be used concomitantly with other long-term HAE prophylactic therapies (e.g., Andembry, Dawnzera, Takhzyro, other C1-INH products). The requested medication will not be used for acute treatment of HAE attacks (acute use is investigational and not eligible for reimbursement).

Combination long-term prophylactic therapy is not recommended and is a condition for denial; acute treatment requests are investigational.

Continuation / Established Therapy

Covered when ALL of the following are met:

Criteria for patients already on Cinryze/Haegarda

A. Diagnosis confirmed: Functional C1-INH protein level < 50% of normal AND serum C4 < 14 mg/dL AND C1-INH level < 19.9 mg/dL
B. Prescriber: Prescribed by or in consultation with an allergist, immunologist, hematologist, or a physician specializing in HAE or related disorders
C. Clinical response: Favorable clinical response while on therapy (e.g., decreased attack duration, quicker symptom relief, complete resolution of symptoms, or decreased frequency/severity of HAE attacks)
D. Reduced on-demand use: Reduction in utilization of on-demand acute therapies (e.g., Berinert, Ruconest, Firazyr, Kalbitor) as determined by claims while on Cinryze/Haegarda therapy
E. Age: If the requested drug is Cinryze or Haegarda, patient is 6 years of age or older
F. Site of care: Site-of-care medical necessity is met

Concomitant therapy restriction for continuation: Request must confirm the medication will not be used concomitantly with other long-term HAE prophylactic therapies; combination prophylactic therapy is not recommended and may be denied.

Operationally verify no concomitant long-term prophylactic agents are being used.

Dosing

Dosing must meet the following product-specific regimens:

Cinryze dosing: Age ≥ 12 years: 1,000 units IV every 3 to 4 days; doses ≤ 2,500 units (≤100 units/kg) every 3–4 days may be considered based on individual response. Children 6 to 11 years: 500 units IV every 3 to 4 days; adjust based on individual response up to 1,000 units every 3 to 4 days.

Haegarda dosing: Subcutaneous: 60 units/kg every 3 or 4 days.

Coding

Covered HCPCS Codes requiring prior approvalHCPCSCovered

J0598	Injection, C-1 esterase inhibitor (human), Cinryze, 10 units
J0599	Injection, c-1 esterase inhibitor (human), Haegarda, 10 units

Laboratory thresholds for diagnosis — HAE

Functional C1-INH< 50% of normal (laboratory reference values)

Serum C4< 14 mg/dL (laboratory reference values)

C1-INH protein level< 19.9 mg/dL (laboratory reference values)

Provider Actions & Authorization

Prior Authorization

Prior Authorization & Site-of-Care

Prior approval is required for Cinryze (HCPCS Code J0598) and Haegarda (HCPCS Code J0599). Initial and renewal requests are subject to site-of-care management; when billed under the medical benefit, administration is restricted to non-hospital facility-based locations (e.g., home infusion provider, provider office, free-standing ambulatory infusion center) unless the member meets site-of-care exception criteria.

Prior approval required: HCPCS J0598, J0599
Site-of-care restriction: non-hospital facility-based locations unless exception criteria met

Step Therapy

Concomitant Prophylactic Therapy Restriction

The requested medication must not be used concomitantly with other long-term HAE prophylactic therapies (e.g., Andembry, Cinryze, Dawnzera, Haegarda, Takhzyro). Combination therapy for long-term prophylactic use is not recommended and may result in denial of coverage.

Concomitant prophylactic therapies affected: Andembry, Cinryze®, Dawnzera, Haegarda®, Takhzyro
Combination long-term prophylactic use not recommended — may be denied

Denial Risk

Acute Treatment Not Covered

Requests for use of Cinryze or Haegarda for acute treatment of hereditary angioedema attacks will be considered investigational and are not eligible for reimbursement.

Acute treatment with Cinryze or Haegarda — not covered / investigational

Documentation Required

Documentation & Potential Denials

The Company may request additional documentation to support medical necessity and to process coverage determinations. Documentation may include patient medical records, test results, and provider credentials. The Company may deny reimbursement if the drug or services are determined to be not medically necessary, investigational/experimental, outside the member's benefit scope, or part of an inappropriate or excessive billing pattern.

Documentation may include patient records, test results, provider credentials
Denial reasons: not medically necessary, investigational/experimental, not within benefit scope, inappropriate/excessive billing

Note

Review, Edits & Appeals Process

Claims received with HCPCS Code J0598 or J0599 will edit with Remark Code M3M or M4M M6J and be adjudicated per Corporate Medical Policy. Prior approval requests that meet policy criteria may be authorized by a nurse reviewer; requests not meeting criteria will be forwarded to a physician consultant. Appeals follow the same review escalation.

Claims edit: HCPCS J0598, J0599 — Remark Code M3M or M4M M6J
Prior approval authorizations: nurse reviewer if criteria met; physician consultant if not met
Appeals: nurse reviewer if documentation meets criteria; otherwise Chief Medical Officer or specialty physician consultant review

Background

Hereditary angioedema (HAE) is a rare disorder caused by deficiency or dysfunction of the C1 esterase inhibitor (C1‑INH), resulting in recurrent episodes of nonpruritic, nonpitting subcutaneous or submucosal angioedema that can be life‑threatening when the airway is involved. Plasma‑derived C1‑INH products such as Cinryze and Haegarda are indicated for routine long‑term prophylaxis in eligible patients; laboratory confirmation for HAE includes functional C1‑INH < 50% of normal and supportive low complement levels (e.g., serum C4 < 14 mg/dL and C1‑INH level < 19.9 mg/dL), and specialist involvement is required for prescribing.

Definitions

HAE Type I vs Type II

Type I HAEMutations causing decreased production of C1-INH leading to decreased functional levels

Type II HAEMutations associated with a dysfunctional C1 inhibitor with normal inhibitor level

InheritanceAutosomal dominant mutations in the C1-INH gene (chromosome 11q)

Short-term prophylaxis — peri-procedural dosing and timing

Recommended short-term prophylaxis dosing10–20 U/kg or 1,000 units administered 1 to 6 hours before the procedure

Typical timingAdministered 1 to 6 hours prior to procedures associated with more than minor manipulation, prior to intubation, or major procedures

Context for useUsed to prevent HAE attacks triggered by procedures or airway instrumentation